Investor Presentation
Setting the new standard for cannabis-based nutraceuticals and sports medicine therapies
Investor Presentation Setting the new standard for cannabis-based - - PowerPoint PPT Presentation
Investor Presentation Setting the new standard for cannabis-based nutraceuticals and sports medicine therapies ALIGNED WITH POWERFUL TRENDS US $22 Billion Expected size of Canadian cannabis market (recreational and medical) by 2022 US $70
Setting the new standard for cannabis-based nutraceuticals and sports medicine therapies
0 1 | O R I O N N U T R A C E U T I C A L S | I N V E S T O R P R E S E N T A T I O N
Orion is well-positioned to capitalize on powerful emerging trends in both the international cannabis and nutraceutical sectors and to become a world- class brand differentiated by the quality, variety, price point, and marketing of our products. Orion is executing a comprehensive plan to become a global leader in the production of medical and recreational cannabinoid extracts and oils, nutraceuticals, and pharmaceuticals.
US $22 Billion by 2022
Expected size of Canadian cannabis market (recreational and medical)
US $70 Billion by 2022 US $52 Billion by 2022 80% of the total market
US $500 Billion
Projected size of the total cannabis market within the United States Anticipated global market size
Market share of cannabis extracts, oils, and other derivatives produced after extraction (versus 20% for dried bud) Potential size of the of the eventual international consumer market for cannabis (medical & recreational)
0 2 | O R I O N N U T R A C E U T I C A L S | I N V E S T O R P R E S E N T A T I O N
MISSION
Diversified, high-margin revenue streams (products & oils) Orion Nutraceuticals will set a new standard within Cannabis Life Sciences by producing and developing innovative products with key strategic partners in the
include low production costs, industrial-scale, high-quality, and global distribution. In order for the cannabis industry to reach its full potential it must reliably supply consumers with a variety of high-quality, tested, consistent, and safe products at an affordable price. All these are key strengths and capabilities of Orion.
WHY ORION?
HIGH-POTENTIAL PLATFORM <5¢ cost/gram of dried flower (Colombia) Distribution channels in NA, EU, LATAM Pipeline of relationships & acquisition targets Industry-proven senior management team LESS OPERATIONAL RISK Rigorous, transparent governance model Execution, construction, operating expertise Large scale cultivation & extraction know-how 40+ potentially patentable formulations MEANINGFUL INNOVATION Portfolio of unique sports medicine products Advancements in new ingestion methods Developing target, high-resin genetic strains
FUNDING REQUIREMENTS
PROJECTED USE OF PROCEEDS
Office & Admin 25% Advertising & Marketing 10% Building & Equipment 65%
ORION IS SEEKING EQUITY GROWTH CAPITAL: ORION NUTRACEUTICALS IS PUBLICLY LISTED ON THE CANADIAN STOCK EXCHANGE (CSE: ORI) AND IS IN THE PROCESS OF ACQUIRING HEALTH CANADA PRODUCTION, DISTRIBUTION, IMPORT/EXPORT LICENSES
0 3 | O R I O N N U T R A C E U T I C A L S | I N V E S T O R P R E S E N T A T I O N
CCO, Director
Marcelin O'Neill
Independent Director
Robin Linden
CEO, Director
Jonathan Fiteni
CFO, Director
Christopher Cherry
The Orion senior management team possesses significant industry experience (including as a licensed producer), deep relationships, access to the most recent cultivation and production technologies, and specialized cannabis and capital markets knowledge on par with the largest publicly listed companies in the sector.
Jonathan Fiteni is a cannabis pioneer who has worked over 15 years to actively bridge the divide between global investment capital and legal growers, suppliers, researchers, and medical professionals who have dedicated their lives to transforming the cannabis industry.
startups, raised millions in capital for both private and public companies and developed more than 40 patent pending cannabis formulations. Most recently Mr. Fiteni was the CEO and Director of Operations for MYM Nutraceuticals, Inc. a publicly listed (CSE) company focused on building large, licensed production facilities to serve the pharmaceutical-grade and recreational cannabis markets.
Columbia Institute of Technology with a Business Administration and Management degree. Christopher Cherry has over 15 years of corporate accounting and audit experience, having been a Chartered Accountant (CA) since February 2009 and a Certified General Accountant (CGA) since 2004.
level positions, including as a Senior Accountant at KPMG and as an Auditor at Davidson and Co. LLP in Vancouver.
director and officer levels for a number
is the founder of Cherry Consulting, Ltd.
Technology in Accounting from the British Columbia Institute of Technology. Marcie O'Neill brings over 24 years of experience in the management of public companies, including expertise in the areas of corporate governance and affairs, regulatory and compliance, and financial/operational oversight.
Accrete Consulting, Inc., which delivers corporate governance and management services to public companies.
a number of firms, including Alternate Health Corp., Jagercor Energy Corp., Cervantes Capital Corp., and Mandalay Resources Corporation.
Columbia Institute of Technology with a degree in Business Management. Ms. O'Neill has also successfully completed the Canadian Securities Course and the Conduct and Practices Handbook, both with Honours. Robin Linden contributes over 20 years of leadership and management experience, including roles at the University of Manitoba, Molson Breweries Canada, Canadian luxury retailer – Holt Renfrew, and Fairmont Hotels and Resorts.
a publicly traded Canadian medical cannabis company. He has been instrumental in initiating various projects, including the current construction of over 2.7 million square feet of cannabis production space in Canada and Australia. Mr. Linden brings with him experience in the branding and sales of a variety of cannabis-based products.
degree (with honours) from the University of Manitoba and obtained post graduate diplomas from both Simon Fraser University (Vancouver) and the University of St. Andrews (Scotland).
Orion will use cannabis extracts and oils as the foundation to develop an innovative line of branded nutraceutical and pharmaceutical products, as well as sell bulk oils to meet global industry demand.
0 4 | O R I O N N U T R A C E U T I C A L S | I N V E S T O R P R E S E N T A T I O N
Orion First Mover Advantages
Medicinal Products
Transdermal Patches Topical Gels Creams Sprays Capsules Tinctures Aerosols Sublingual Medication Buccal Medication Pharmaceutical-Grade Products
Over-the-Counter Products
Personal Care Products Massage Oils CBD Sports Drinks Time-Released CBD Sports Wraps Sports Medicine Products
Bulk Extracts & Oils
Full Spectrum Oils CBD Isolates Other Targeted Cannabinoids Terpenes Micro-Emulsions As the CBD market continues to evolve and expand through increased awareness and advances in research, nutraceutical science is becoming heavily involved. Orion is helping open the door to a new range of CBD-based and CBD-infused products which offer potentially better solutions for pain management, reduced inflammation, faster recovery times, and the offsetting of brain injuries. Orion has an aggressive strategy, in partnership with leading research organizations, professional athletes, and sports leagues, to introduce and promote an innovative line
Retailers, Distributors, Wholesalers Homeopathic Sales Channels Pharmaceutical Sales Channels
Transdermal cannabis patches are a unique method of cannabis
veinous area of the body, and the cannabinoids (cannabis chemical compounds) enter the bloodstream for an effective and long-lasting
amongst other medical benefits. Transdermal applications are an alternative option for users who do not want or cannot, consume cannabis by inhaling or ingesting the medication.
0 5 | O R I O N N U T R A C E U T I C A L S | I N V E S T O R P R E S E N T A T I O N
Orion will work to develop transdermal patches, with formulations including CBD, THC, THC-A, CBG, CBN, and / or other desired blends of cannabinoids. Orion's transdermal patches and topical gels are advisable solutions for the following conditions: Fibromyalgia Peripheral Neuropathic Pain Parkinson's Disease Schizophrenia Autism Post-Traumatic Stress Disorder (PTSD) Epilepsy (99% CBD formulation) Multiple Sclerosis Dravet Syndrome
More uniform plasma levels as delivery are controlled through the skin and into circulation Simple removal of the patch can reverse any potential adverse side effects, allowing for a more controlled and comfortable experience No "peaks" and valleys" as seen with oral administration (inhaling or ingesting cannabis) A non-invasive method of cannabis consumption Avoids first-pass effects with increased bioavailability Improved patient compliance due to the reduced dosing frequency Reduced side effects due to the reduction of peaks in plasma levels
0 6 | O R I O N N U T R A C E U T I C A L S | I N V E S T O R P R E S E N T A T I O N
MEDIC OASIS (ACquisition) ORION NUTRACEUTICALS fcm global (joint venture)
Canada-based (Dorval, Quebec) 20,000 ft2 vertical farming 1,300 Kg/year of Cannabis Oil 6,500 Kg/year of Dry Flower Canada-based (Vancouver) 255,800 ft2 indoor growing 46,300 Kg/year of Cannabis Oil 381,500 Kg/year of Dry Flower Colombia (Medellin, La Ceja) 235,800 ft2 production facility 300+ Ha of additional land (Tolima) 45,000+ Kg/year of Cannabis Oil
CLEAR VALUE PROPOSITION
Orion's nimble structure and partnerships / acquisitions offer substantial benefits to all stakeholders and give the company a significant competitive advantage.
FURTHER GROWTH OPPORTUNITIES
Orion has developed both global reach and local engagement over the last several years, with future expansion potential under review in Greece & Macedonia. Orion products will be produced, tested, and distributed to harmonized GAP and GMP standards of quality
0 7 | O R I O N N U T R A C E U T I C A L S | I N V E S T O R P R E S E N T A T I O N Colombia features established agribusiness (#2 globally for exports of coffee and cut flowers) and pharmaceutical sectors, as well as 45+ international free trade agreements, including economic treaties with Argentina, Brazil, Canada, Chile, Mexico, Peru, and Uruguay - all countries with existing or emerging medical/recreational cannabis laws.
E Q U A T O R E Q U A T O R
Equatorial climate with 12/12/365 daily light cycle
M E D E L L Í N
C O L O M B I A
B O G O T Á
POSSIBLY THE BEST PLACE ON EARTH TO SUSTAINABLY GROW CANNABIS AT SCALE A COUNTRY OF MANY SURPRISES AND AN UNMATCHED TRANSFORMATIONAL STORY
Top world ranks for water availability & precipitation Elevations ranging from 0 to 13,125 ft above sea level #1 in world: flora species/square mile, #2 in biodiversity 21 million Ha of land suitable for agricultural expansion Hundreds of strains in their natural environment LATAM's most advanced cannabis regulatory framework Patient-friendly laws; high approval for medical cannabis Population of 49 million people (55% under the age of 30) 10 major cities with more than 500,000 inhabitants 2x landmass of California, 3x landmass of Germany Dynamic research community and cannabis talent pool Gateway between The Americas; access to two oceans
L A C E J A N A T A G A I M A , T O L I M A
0 8 | O R I O N N U T R A C E U T I C A L S | I N V E S T O R P R E S E N T A T I O N
FCM Global's Co-Source Colombia model complements Orion's downstream product development focus, enabling outsourced lower-cost cultivation and extraction without compromising customization, consistency, or
Colombia and across LATAM. FCM's platform is designed to flexibly integrate to Orion's business requirements.
FINISHED ORION PRODUCTS LOW-COST OIL FOR ORION OILS IN BULK FOR SALE UNIQUE STRAINS CULTIVATION AT SCALE EFFICIENT EXTRACTION
TRUSTED BRAND ABLE TO FILL LARGE PURCHASE ORDERS TRUSTED SUPPLY PARTNER ABLE TO KEEP PACE WITH ORION
DEVELOPMENT OF NEW VALUE-ADDED PRODUCTS
New Standards in Nutraceuticals Co-Source with Confidence
FCM's CAPABILITIES + COLOMBIAN COMPARATIVE ADVANTAGES WILL HELP SUPPORT ORION'S STRATEGIES FOR DIFFERENTIATED POSITIONING AND LONG-TERM PROFITABILITY Product Quality Competitive Pricing Availability & Variety Professional Team Proven Pilot Operation
EXPANDED DISTRIBUTION CHANNELS
Fully Licensed Producer
0 9 | O R I O N N U T R A C E U T I C A L S | I N V E S T O R P R E S E N T A T I O N
FCM Global is building a solid production-focused company. As Colombia's first fully licensed producer (August 2017) and exporter (September 2017) for non-psychoactive cannabis for medical and research purposes, FCM is also in the final stages of receiving its high-THC licenses (anticipated mid-Q4 2018 approval). FCM is well-positioned to produce and supply a wide range of CBD and THC extracts, isolates, seeds, and strains to support Orion and to distribute internationally
Proprietary advanced genetics & cloning programs (indoor, outdoor strains)
Fully non-psychoactive licensed (grow, produce, export) Purpose-built platform for Colombian medical cannabis Soil-to-Oil: genetics, grow, extract, package, distribute Site design optimized for production capacity & efficiency
High-efficiency extraction with total
Enclosed naturally sunlit greenhouses and sustainable methods In-house quality testing lab plus independent CoAs
Existing 235,800 ft2 production facility (La Ceja) Designed & operated to GAP and GMP standards Integrated ERP system with seed-to-sale traceability Replicable blueprint to drive future expansion (Tolima) 12 Month Execution
1 0 | O R I O N N U T R A C E U T I C A L S | I N V E S T O R P R E S E N T A T I O N FCM has fully secured a 450+ hectare property in Natagaima, Tolima Colombia Over 300 hectares suitable for controlled outdoor cultivation (CBD, THC strains) Additional 150+ hectares suitable for centralized production / export infrastructure Further onsite capacity to develop, manufacture, distribute finished products Potential to achieve US $1 billion in revenues by YE 2023 (3-4 stage development) Enables production costs of < 4¢ per gram for dried flower and < 15¢ per gram of oil Strategic location: non-conflict agricultural area with favorable free zone potential Indoor propagation, controlled outdoor cultivation (leveraging La Ceja pilot program) FCM production licenses are extendable to new properties and partnerships Initial suitability tests have been successful; enthusiastic local government support
1 1 | O R I O N N U T R A C E U T I C A L S | I N V E S T O R P R E S E N T A T I O N
Medic Oasis, Inc. is a Quebec-based company currently in Stage 5 of its Health Canada application process. Quebec is Orion's Canadian production headquarters and the next step in building a global footprint. Medic Oasis, when licensed, is strategic to Orion as a 99% owned subsidiary for both expanding its presence in the Canadian cannabis sector, as well as to enable import/export of oil from Colombia (via FCM) to other parts of Canada, Europe, and wider international markets. Medic Oasis will be an instrumental part of Orion's development efforts for certain strains, potent extracts, nutraceuticals, and pharmaceuticals which incorporate cannabis and cannabis-based medical science.
MEDIC OASIS HIGHLIGHTS
Canadian-based grower / supplier of cannabis and cannabis-based products Currently in the advanced stages of becoming an ACMPR Licensed Producer Planned 20,000+ ft2 production facility in Dorval, Quebec (Q2 2019 completion) Medic Oasis will be Orion's first growing facility (vertical growing techniques) Additional in-house lab support services and R&D capabilities
1 2 | O R I O N N U T R A C E U T I C A L S | I N V E S T O R P R E S E N T A T I O N
O R I O N F I N A N C I A L P R O J E C T I O N S O R I O N C A P T A B L E S U M M A R Y
C O N T A C T O R I O N : 300 – 1055 West Hastings St. Vancouver, BC, V6E 2E9 Tel: (604) 609-6196
www.orionnutraceuticals.com & .ca jf@orionnutra.ca Jonathan Fiteni, CEO